Systematic Review of Parotid Gland Sarcomas: Multi-Variate Analysis of Clinicopathologic Findings, Therapeutic Approaches and Oncological Outcomes That Affect Survival Rate.
head and neck malignancies
parotid gland
review
sarcoma
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Oct 2022
05 Oct 2022
Historique:
received:
10
08
2022
revised:
25
09
2022
accepted:
03
10
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
The aim of this study was to systematically review the literature of sarcoma of the parotid gland in order to analyze the main factors affecting survival rate. A systematic literature review was performed between January 1990 to November 2021, and 88 patients affected by parotid gland sarcomas were included. The most common histological types were Rhabdomyosarcoma and Synovial Sarcoma. From our review, it emerges that primary sarcomas of the parotid glands are locally aggressive but show low tendency to metastasize to the lymph nodes of the neck and that surgery (i.e., total or radical parotidectomy) is the main approach for their treatment. The global overall survival (OS) is 52% at 5 years and 34.1% at 10 years. The OS for T1, T2, T3, T4 tumor at 5 years of follow up is 80.0%, 66.5%, 56.7% and 33.3%, respectively. Size/extension at the diagnosis and the sarcoma's histotype are the most important prognostic factors. Multivariate analysis showed that surgery (total or radical parotidectomy) performed on the tumor (
Identifiants
pubmed: 36230786
pii: cancers14194862
doi: 10.3390/cancers14194862
pmc: PMC9563272
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Treat Res Commun. 2021;26:100268
pubmed: 33340903
Otolaryngol Head Neck Surg. 2017 Dec;157(6):988-994
pubmed: 28675085
Head Neck Pathol. 2022 Jun;16(2):353-365
pubmed: 34251596
Head Neck. 2019 Jul;41(7):2359-2366
pubmed: 30779403
Cancer. 1986 Sep 15;58(6):1305-15
pubmed: 3742455
Otolaryngol Head Neck Surg. 2006 May;134(5):717-23
pubmed: 16647522
Cells. 2021 Oct 30;10(11):
pubmed: 34831178
Ann Surg Oncol. 2004 Jun;11(6):619-28
pubmed: 15172935
Mayo Clin Proc. 2007 Nov;82(11):1409-32
pubmed: 17976362
Adv Otorhinolaryngol. 2016;78:141-7
pubmed: 27093301
Cancer. 2003 May 15;97(10):2530-43
pubmed: 12733153
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
CA Cancer J Clin. 2020 May;70(3):200-229
pubmed: 32275330
Eur Arch Otorhinolaryngol. 2008 Jul;265 Suppl 1:S47-56
pubmed: 17934743
Eur Arch Otorhinolaryngol. 2022 Jun 9;:
pubmed: 35678874
EMBO Mol Med. 2020 Nov 6;12(11):e11131
pubmed: 33047515
Arch Otolaryngol Head Neck Surg. 1991 Mar;117(3):302-6
pubmed: 1998570
Curr Oncol Rep. 2002 Jan;4(1):68-75
pubmed: 11734116
Head Neck. 2013 Nov;35(11):1551-7
pubmed: 23728801
Ann Oncol. 2013 Aug;24(8):2181-9
pubmed: 23562930